Had a nice call with Heather Stombaugh, MBA this morning who reminded me of an aricle I was sent yesterday in my #jdrf Insider News email. This JDRF funded study recently published in the #nejm showing the importance of cell signaling pathway(s) in the progression in patients developing #t1d. Treatment of those patients with #baricitinib (a JAK inhibitor, where Janus Kinase is important in cell signaling, growth and survival) showed no significant decrease in C-peptide levels during the study, which is a well established marker of endogenous insulin production. This is another study showing significant results in preserving pancreatic beta-cell function. Baricitinib is known to and used to treat a number of #autoimmunedisease and chronic inflammatory disorders and also is crucial in downregulating cell signaling pathways involved in immune regulation and inflammatory response. This is another important piece in looking at specific mechanisms of decreasing immune response in autoimmune disease but also looking at specific cell signaling pathways to preserve beta-cell function. This important work being funded by #jdrf is another valuable piece into disease modification for those already living with Type 1 diabetes while additional work looks for prevention prior to diagnosis.
Chris Howard’s Post
More Relevant Posts
-
Interested in #T1D and potential stem cell treatments to “replace” pancreatic beta-cells destroyed by this #autoimmune disease? Another study publication, this time from a center in Canada, utilizing the technology being developed by Vertex. The progress being demonstrated by these studies, and the hope it can offer patients with no detectable endogenous insulin production is amazing. I look forward to continued further advancements of the technology and additionally those offering an option with no need for immunosuppressant therapy in conjunciton.
Stem Cell-Derived Beta Cells Show Promise for Blood Sugar Control in Type 1 Diabetes Patients, New Study Reveals
medicaldialogues.in
-
Interested in insulin pumps, hybrid closed loop automated insulin delivery systems and affect on blood sugar and then A1c results? See below for an interesting paper. As a user of the Medtronic MiniMed 780g I found the below paper an insightful study on Tight Time In Range (TTIR, or in other words 70-140mg/dL) and hopefully leading to potential improved clinical outcomes for those of us with #T1D. I try and use the hybrid closed loop system to it's full capabilities, leaving it in SmartGuard (or automode as it used to be called, letting the system vary insulin delivery with CGM input), have it set to a blood sugar target of 100mg/dL and 2 hour active insulin time. Now it has me thinking I need to pull down a few months of data and compare my results to these outcomes! https://lnkd.in/erG4zXdS
12-Month Time in Tight Range Improvement with Advanced Hybrid-Closed Loop System in Adults with Type 1 Diabetes - Diabetes Therapy
link.springer.com
-
For those of you interested in another study showing how the immune system is triggered to attack insulin-producing cells, leading to the development of #T1D, check out the following article: https://lnkd.in/e4R69nRf An interesting study showing how some bacterial proteins activate killer-T cells in the immune system and initiate destruction of the pancreatic beta-cells. As deeper understanding continues to develop on the triggers and pathways leading to this #autoimmune destruction I hope that corresponding immunological intervention pathways emerge to halt, reverse and even cure Type 1 diabetes.
-
Another interesting therapeutic project in the #T1D space. A recent update from Breakthrough T1D (aka JDRF) on their funding of this novel liquid nanoparticle (LNP) delivery system for mRNA-encoded antigens and immune-modifying small molecules. The combination of these is designed to reprogram the immune system to help protect and preserve pancreatic beta-cell function in the disease progression of Type 1 Diabetes. Take a quick look at the overview article to learn more about this novel therapeutic project.
Integrated Nanotherapeutics secures funds to develop T1D therapy
pharmaceutical-technology.com
-
For those in my network interested in #T1D and particularly interested in disease-modifying therapies to arrest the progression of Type 1 diabetes, preserve pancreatic beta-cell function, and possibly even remission of disease, this article is for you. This is a fascinating #proteomics study looking for plasma biomarkers in newly diagnosed T1D patients and trying to yield patient specific profiles which could be used to stratify patients for future therapeutics. This would certainly be a welcome addition to those developing future therapeutic solutions - biomarkers to assess patient populations that would benefit from the specific therapy. Well worth your time to read if you have not already. https://lnkd.in/e-2dRJKm
Plasma proteomics in children with new-onset type 1 diabetes identifies new potential biomarkers of partial remission - Scientific Reports
nature.com
-
Over the past few days I’ve been following my colleague Nara Daubeney PhD’s updates on this Innovate UK funding fiasco (? Is that the best word? I will use it for now regardless). It is hard to engender trust in a system which commits to one thing but doesn’t follow through on that commitment….until they are essentially forced to by bad PR. I am sure that many of these applicants deserved the award they ultimately received and many who did not receive anything probably deserved them as well. I cannot believe this still happens in 2024. Thank you for bringing attention to this Nara!
Pressure is continuing to grow on Innovate UK despite their U-turn over their flagship Women in Innovation Awards. Yesterday BusinessCloud published an investigation on how the campaign against Innovate UK started with a single email to Liverpool-based FemTech entrepreneur Emma Jarvis and the story has been shared around the world. High profile Cindy Gallop, who is based in New York and is the founder of MakeLoveNotPorn, shared the story to her 122,000 followers with the message: “I’ve been urging women for decades to get very, very angry – because when we get angry, we make shit happen. “Nothing demonstrates this better than Emma Jarvis, Tara Attfield-Tomes, Zandra Moore and Becky Lodge and how they mobilised female founders around Innovate UK’s appalling fail to get Innovate UK to reverse their position within hours, and to spark a bigger conversation about how investors everywhere are failing to fund female founders. “Women, read this for future reference the next time investors f*ck us over – and investors: are you the kind of investor who talks about funding female founders, or are you the kind that writes cheques?” Hundreds of other people have joined the debate including Laura Wharton (She/Her), employment partner at JMW Solicitors, who asked: “Don’t we think Innovate UK needs to explain in detail what’s gone on here, the original decision and how it was reached and the change of ‘heart’?” Sandy Lindsay MBE Lindsay, chair of Tangerine Group, said: “About time Innovate UK have been bought to task – I’ve always had deep suspicions about the way they operate, not just from a gender point of view but something I couldn’t ever quite put my finger on.” Carla Ottersen is the CMO of Silent Sensors and actively supports female founders. She said: “Don’t forget the hundreds of Women in Innovation applicants who acted collectively from the very moment we got that miserable email from Innovate UK." Karla Morales-Lee, co-founder of Warrior Group, said: “None of us are doing this to get a grant for our business. It’s women (and some very impassioned equally ducked off male allies) wanting us all to rise.” Angela Rawstorne AIEMA wrote: “Power to the female investor.” Applied Futurist Tom Cheesewright said: “Yet again women have to work twice as hard just to get what’s theirs." Tasnim Khalid, managing partner, Private Client Solicitors, said: “So many female founders have been deeply affected by this but the support has been phenomenal.” Lauren Stiebing, founder and CEO of LS International, said: “Amazing to see the power of collective advocacy leading to tangible change. Here’s to more funding, more innovation, and a brighter future for female founders.” Claudia Stankler, COO of Connectd, said: “It’s so inspiring to see what women can do when we are listened to, but it’s a shame we are even put in that position in the first place.” https://lnkd.in/eP6iKRfm
-
-
The number of study participants is quite small but it is interesting to read of the effects of aerobic exercise on #T1D patients and the differences observed in male vs female participants. I had never contemplated too deeply that running could have different glycemic effects based on gender in the Type 1 Diabetes population. I would be very interested to read more on the subject on studies with significantly more data points. Short article you might find interesting Adam Rosenfield Brooke Kaplan, SHRM-SCP Casey Boren https://lnkd.in/eR9wbwRt
Best exercises for people with type 1 diabetes outlined in new research
diabetes.co.uk
-
Great opportunity to influence the direction of an outstanding organization!
#CallForNominations - We are accepting nominations for the next International Diabetes Federation Board of Directors (2025-26). The elected candidates will play a vital role in shaping our strategic plan and contribute to our innovative programmes. Do you know a committed leader with a proven track record of driving change for people living with diabetes on a global scale? Nominations are accepted until 30 September. Learn more: https://lnkd.in/d-ytSHqE
-
-
Interested in learning more about screening in #T1D? With the continued advancement of potential disease modifying therapies, including those achieving regulatory approvals, the work continues to better identify those likely to develop Type 1 Diabetes long before clinical manifestation. It is well established now that avoiding ketoacidosis in undiagnosed diabetic patients has long term health benefits (and much less traumatic for the patients) so that identifying at risk populations becomes a continuing evolving and improving field. Currently markers of autoimmunity are crucial to the patient population segregation but this article does a nice job looking at other areas like GWAS and interestingly lipidomics, offering insights in to better understanding potential earlier biomarkers for T1D screening, potential even as a tool for newborn screening prior to immune system maturation. For those of you interested in the topic, I hope you find the following article of interest.
A Review of Stage 0 Biomarkers in Type 1 Diabetes: The Holy Grail of Early Detection and Prevention?
mdpi.com
-
I get asked many questions about my CGM (I've been wearing it on my arm for years now, so summer clothes or when I'm out running it's quite easy to spot) and usually it's an easy give away to strike up conversations with people because they "must be diabetic like me". The good news for all of you is that you can now get a CGM from Dexcom over the counter (in the U.S. at least) but will make my diabetes conversations a little more challenging. The exciting thing for many non-diabetics is that they will be able to track and analyze their blood sugar readings before, during after after exercise, as you see many elite endurance athletes do already. So all of my "normal runners" (ha ha) you now have access to some pretty interesting data which can definitely be used to improve your endurance training and performance!
First Over-the-Counter Continuous Glucose Monitor Launches
medscape.com
